thyroid-stimulating hormone receptor

ML-109 is a potent agonist of thyroid stimulating hormone receptor (TSHR) (EC50 of 40 nM)

NCGC00229600 is an allosteric inverse thyrotropin receptor (TSHR) agonist. NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenously and can be used in Graves' disease studies.

D3-βArr (NCGC00379308) is a positive allosteric modulator for thyrotropin receptor (TSHR), which initiates translocation of β-Arr 1 (EC50: 11.6 μM) by direct TSHR activation.

2,2-BIS(2-HYDROXY-5-BIPHENYLYL)PROPANE is targets the thyroid stimulating hormone receptor (human)

TSHR antagonist S37a is a selective, orally bioavailable TSHR (thyroid-stimulating hormone receptor) antagonist that inhibits TSH-induced cyclic adenosine monophosphate (cAMP) in TSHR-expressing HEK 293 cells, suitable for studying Graves' orbitopathy.

Org41841 is an agonist of luteinising hormone/chorionic gonadotropin receptor and thyroid stimulating hormone receptor (EC50s: 0.2 and 7.7 μM, respectively) and can be used to study hyperthyroidism.

NCATS-SM4420 (Compound A35) is an orally effective ligand for the thyroid-stimulating hormone receptor (TSHR) that inhibits the proliferation of MDA-T32 and MDA-T85 cells both in vitro and in vivo, with IC50 values of 0.71 μM and 0.38 μM, respectively. Additionally, it suppresses the metastasis of MDA-T85F1 in mice. NCATS-SM4420 holds potential for research in the field of thyroid cancer.

ADX61623 is an effective negative allosteric modulator (NAM) of the follicle-stimulating hormone receptor (FSHR). It also exhibits activity on the luteinizing hormone receptor (LH-R) but is inactive on the thyroid-stimulating hormone (TSH) receptor. ADX61623 can be utilized in research on estrogen-dependent diseases.

Org 274179-0 is an effective allosteric antagonist of the thyroid-stimulating hormone (TSH) receptor, with an IC50 in the nanomolar range. It fully inhibits TSH (and TSI)-mediated activation of the TSH receptor with minimal impact on the efficacy of TSH. This compound can be utilized in studies of Graves' disease (GD).

Org 274178-0 is a selective antagonist of the thyroid-stimulating hormone receptor (TSHR), with a pIC50 value of 5.03 for TSHR. It inhibits the activation of the cAMP and phospholipase C (PLC) signaling pathways mediated by thyroid-stimulating hormone (TSH) and TSH receptor-stimulating immunoglobulins (TSIs). Org 274178-0 shows potential for research in Graves' disease and Graves' ophthalmopathy.

Anti-TSHR Antibody (M22) is a and highly specialized stimulating monoclonal antibody that targets the thyrotropin receptor (TSHR) to mimic the biological activity of thyroid-stimulating hormone and facilitate the measurable activation of cyclic AMP signaling pathways across various endocrine and immunological experimental models.